Cytox is a brand that specializes in non-invasive risk assessment and patient stratification tools for Alzheimer's disease and dementia. They aim to transform the development of new treatments, screening methods, and patient management within the Alzheimer's disease care pathway. With an increasing number of individuals affected by Alzheimer's disease worldwide, Cytox's products and services have become crucial in addressing the growing problem.

Cytox offers two products powered by their geno SCORE™ technology. In the US, they have partnered with Sampled to provide the Sampled Alzheimer's Risk Test - powered by geno SCORE. In Europe, Cytox collaborates with Yourgene Health to offer geno SCORE-LAB.

These tests require only a blood or saliva sample, and the results provide valuable insights into an individual's genetic risk of cognitive decline due to Alzheimer's disease. Their geno SCORE tests are beneficial for physicians assessing new patients and can also be used in clinical study recruitment strategies. Additionally, Cytox has geno TOR™, which is currently used for research purposes.

It characterizes an individual's genetic profile linked to mTOR-regulated signaling pathways. Cytox has received funding from The European Union's Horizon 2020 research and innovation program. With their innovative approach and dedication to Alzheimer's disease research, Cytox is at the forefront of addressing this global health challenge